Literature DB >> 9097494

Velopharyngeal function in cleft patients undergoing maxillary advancement.

M L Haapanen1, M Kalland, A Heliövaara, J Hukki, R Ranta.   

Abstract

Maxillary advancement may result in movement of the posterior border of the hard palate with its soft palate attachment, which may cause impairment of velopharyngeal (VP) function. We examined VP function before and after Le Fort I osteotomy in 15 cleft lip and palate patients. The extent of maxillary advancement was measured by means of standard cephalometric radiographs taken before and after the operation. VP function was evaluated in terms of perceptual speech assessments, pressure-flow data and nasalance scores preoperatively and 2, 6 and 12 months after the operation. The results showed that maxillary advancement resulted in impairment of VP function in 4 (27%) of the patients.

Entities:  

Mesh:

Year:  1997        PMID: 9097494     DOI: 10.1159/000266436

Source DB:  PubMed          Journal:  Folia Phoniatr Logop        ISSN: 1021-7762            Impact factor:   0.849


  3 in total

1.  Correlation of morphological variants of the soft palate and Need's ratio in normal individuals: A digital cephalometric study.

Authors:  Pradhuman Verma; Kanika Gupta Verma; Kikkeri Lakshminarayana Kumaraswam; Suman Basavaraju; Suresh K Sachdeva; Suruchi Juneja
Journal:  Imaging Sci Dent       Date:  2014-09-17

2.  Dimensions of Velopharyngeal Space following Maxillary Advancement with Le Fort I Osteotomy Compared to Zisser Segmental Osteotomy: A Cephalometric Study.

Authors:  Furkan Erol Karabekmez; Johannes Kleinheinz; Susanne Jung
Journal:  Biomed Res Int       Date:  2015-07-26       Impact factor: 3.411

3.  Prebiotic-Induced Anti-tumor Immunity Attenuates Tumor Growth.

Authors:  Yan Li; Lisa Elmén; Igor Segota; Yibo Xian; Roberto Tinoco; Yongmei Feng; Yu Fujita; Rafael R Segura Muñoz; Robert Schmaltz; Linda M Bradley; Amanda Ramer-Tait; Raphy Zarecki; Tao Long; Scott N Peterson; Ze'ev A Ronai
Journal:  Cell Rep       Date:  2020-02-11       Impact factor: 9.423

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.